Your browser is no longer supported. Please, upgrade your browser.
Settings
CHRS Coherus BioSciences, Inc. daily Stock Chart
CHRS [NASD]
Coherus BioSciences, Inc.
Index- P/E7.74 EPS (ttm)2.27 Insider Own0.50% Shs Outstand71.10M Perf Week-3.09%
Market Cap1.21B Forward P/E13.30 EPS next Y1.32 Insider Trans-46.17% Shs Float63.64M Perf Month-2.22%
Income180.90M PEG3.52 EPS next Q0.41 Inst Own- Short Float27.91% Perf Quarter-7.03%
Sales487.40M P/S2.49 EPS this Y138.10% Inst Trans5.24% Short Ratio18.47 Perf Half Y-0.40%
Book/sh3.00 P/B5.86 EPS next Y-31.09% ROA36.90% Target Price30.22 Perf Year3.96%
Cash/sh6.61 P/C2.66 EPS next 5Y2.20% ROE136.00% 52W Range10.86 - 23.03 Perf YTD-2.30%
Dividend- P/FCF8.63 EPS past 5Y16.20% ROI37.00% 52W High-23.62% Beta1.66
Dividend %- Quick Ratio5.00 Sales past 5Y62.80% Gross Margin93.60% 52W Low61.95% ATR0.72
Employees306 Current Ratio5.20 Sales Q/Q62.70% Oper. Margin41.70% RSI (14)46.27 Volatility4.68% 3.88%
OptionableYes Debt/Eq1.89 EPS Q/Q106.10% Profit Margin37.10% Rel Volume0.76 Prev Close17.00
ShortableYes LT Debt/Eq1.89 EarningsNov 05 AMC Payout0.00% Avg Volume961.75K Price17.59
Recom1.90 SMA20-1.88% SMA50-5.11% SMA200-2.18% Volume732,910 Change3.47%
Jul-16-20Initiated BofA Securities Neutral $20
Apr-17-20Initiated SunTrust Buy $26
Aug-13-19Initiated Mizuho Buy
Aug-02-19Reiterated Maxim Group Buy $25 → $27
Aug-02-19Reiterated H.C. Wainwright Buy $28 → $29
Jun-11-19Initiated Barclays Overweight $30
May-07-19Initiated H.C. Wainwright Buy $28
Aug-28-18Initiated H.C. Wainwright Buy $28
Mar-09-18Reiterated Maxim Group Buy $20 → $15
Aug-08-17Reiterated JP Morgan Overweight $32 → $25
Jun-13-17Reiterated Maxim Group Buy $44 → $40
May-05-17Initiated BMO Capital Markets Outperform $54
Oct-19-16Initiated Robert W. Baird Outperform $40
Sep-07-16Initiated Maxim Group Buy $43
Jul-27-16Initiated Citigroup Buy $36
Jan-20-16Initiated Credit Suisse Outperform
Oct-22-20 04:15PM  
Oct-16-20 09:30AM  
Oct-05-20 09:44AM  
Sep-28-20 05:23PM  
Sep-18-20 11:02AM  
Sep-13-20 10:10AM  
Aug-21-20 09:30AM  
Aug-11-20 03:45PM  
Aug-06-20 08:10PM  
04:02PM  
Aug-03-20 04:48PM  
Jul-30-20 12:33PM  
Jul-17-20 09:30AM  
Jul-16-20 09:30AM  
Jul-14-20 03:49PM  
Jul-09-20 08:56PM  
Jun-19-20 09:30AM  
Jun-15-20 04:05PM  
Jun-12-20 08:31AM  
Jun-03-20 03:35AM  
May-26-20 06:16PM  
12:53PM  
May-21-20 12:47PM  
May-13-20 07:08PM  
May-10-20 10:47PM  
08:59AM  
May-08-20 05:30PM  
01:05PM  
May-07-20 04:08PM  
May-04-20 09:30AM  
Apr-30-20 12:34PM  
Apr-22-20 09:30AM  
Apr-21-20 05:39PM  
Apr-16-20 07:27AM  
Apr-15-20 12:05AM  
Apr-14-20 07:52AM  
Apr-13-20 09:23AM  
Apr-08-20 10:49AM  
Apr-07-20 06:59AM  
Mar-26-20 08:34AM  
Mar-20-20 09:30AM  
Mar-14-20 02:43AM  
Mar-09-20 05:01AM  
Mar-05-20 04:09PM  
07:00AM  
Feb-29-20 08:54AM  
Feb-27-20 04:01PM  
Feb-26-20 09:30AM  
Feb-24-20 09:43AM  
Feb-20-20 11:19AM  
Feb-11-20 11:30AM  
Feb-07-20 12:00PM  
Feb-06-20 09:34AM  
Jan-23-20 11:30AM  
Jan-17-20 08:16AM  
Jan-13-20 08:30AM  
Jan-08-20 08:53AM  
Jan-07-20 11:30AM  
09:59AM  
Jan-03-20 09:55AM  
09:30AM  
09:01AM  
Dec-30-19 09:44AM  
Dec-19-19 11:30AM  
Dec-16-19 09:34AM  
Dec-07-19 12:25PM  
Dec-03-19 08:51AM  
Nov-26-19 11:27AM  
Nov-19-19 09:36AM  
Nov-15-19 11:17PM  
10:08AM  
Nov-12-19 09:30AM  
08:18AM  
Nov-11-19 09:28AM  
Nov-08-19 09:30AM  
Nov-06-19 06:15PM  
04:01PM  
04:01PM  
Oct-29-19 03:16PM  
Oct-28-19 11:18AM  
Oct-26-19 01:22PM  
Oct-21-19 07:44AM  
Oct-18-19 09:30AM  
Oct-15-19 09:30AM  
Sep-25-19 04:37PM  
Sep-20-19 09:30AM  
Sep-10-19 03:18PM  
09:00AM  
Sep-04-19 11:51AM  
Aug-28-19 04:05PM  
Aug-22-19 09:30AM  
09:11AM  
Aug-21-19 09:30AM  
Aug-01-19 07:52PM  
06:55PM  
04:00PM  
Jul-31-19 01:48PM  
Jul-29-19 08:30PM  
Jul-19-19 09:30AM  
Jul-12-19 12:13PM  
Coherus BioSciences, Inc., a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte stimulating colony factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States. Its product candidates include CHS-1420, an adalimumab (Humira) biosimilar candidate and CHS-0214, an etanercept (Enbrel) biosimilar candidate, which have completed Phase III clinical study for treating psoriasis and rheumatoid arthritis. The company is also developing ranibizumab (Lucentis), an ophthalmology biosimilar candidate; CHS-2020, an aflibercept (Eylea) biosimilar candidate; and CHS-131, a small-molecule drug candidate for non-alcoholic steatohepatitis and other metabolic conditions, as well as bevacizumab (Avastin), an oncology biosimilar candidate. Coherus BioSciences, Inc. has license agreements with Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; Daiichi Sankyo Company, Limited; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Anicetti Vincent RChief Operating OfficerOct 19Option Exercise4.773,21715,35751,773Oct 21 04:04 PM
Anicetti Vincent RChief Operating OfficerOct 19Sale17.893,21757,55648,556Oct 21 04:04 PM
Viret Jean-FredericChief Financial OfficerOct 14Sale19.006,144116,73640,423Oct 16 04:19 PM
Anicetti Vincent RChief Operating OfficerSep 17Option Exercise7.605,00038,00153,556Sep 21 05:06 PM
Anicetti Vincent RChief Operating OfficerSep 17Sale18.845,00094,21648,556Sep 21 05:06 PM
Anicetti Vincent RChief Operating OfficerAug 17Option Exercise7.605,00038,00153,556Aug 19 04:23 PM
Anicetti Vincent RChief Operating OfficerAug 17Sale19.375,00096,85148,556Aug 19 04:23 PM
Anicetti Vincent RChief Operating OfficerJul 17Option Exercise11.0015,000165,00163,556Jul 21 05:04 PM
Anicetti Vincent RChief Operating OfficerJul 17Sale18.2515,000273,68748,556Jul 21 05:04 PM
Lanfear Dennis MPresident & CEOJul 01Option Exercise0.0129,994249193,258Jul 06 05:58 PM
Szela Mary TDirectorJun 22Option Exercise8.8454,997485,90054,997Jun 24 04:55 PM
Szela Mary TDirectorJun 22Sale17.5854,997966,7590Jun 24 04:55 PM
Anicetti Vincent RChief Operating OfficerJun 17Option Exercise2.502,5006,25151,056Jun 19 04:35 PM
Wahlstrom MatsDirectorJun 17Sale17.15200,0003,430,0200Jun 19 04:33 PM
Anicetti Vincent RChief Operating OfficerJun 17Sale17.222,50043,05048,556Jun 19 04:35 PM
Viret Jean-FredericChief Financial OfficerMay 20Sale17.661,27822,56946,567May 22 04:30 PM
Anicetti Vincent RChief Operating OfficerMay 18Option Exercise2.502,5006,25151,056May 20 05:01 PM
Anicetti Vincent RChief Operating OfficerMay 18Sale17.173,09353,10748,556May 20 05:01 PM
Anicetti Vincent RChief Operating OfficerApr 20Sale17.005,15087,55047,846Apr 21 04:24 PM
Anicetti Vincent RChief Operating OfficerApr 17Option Exercise2.505,00012,50357,996Apr 21 04:24 PM
Anicetti Vincent RChief Operating OfficerApr 17Sale15.575,00077,85052,996Apr 21 04:24 PM
Wahlstrom MatsDirectorMar 03Sale20.12118,0662,375,409200,000Mar 05 04:31 PM
Viret Jean-FredericChief Financial OfficerFeb 19Option Exercise10.053,15931,74850,000Feb 21 06:16 PM
Viret Jean-FredericChief Financial OfficerFeb 19Sale22.333,15970,55246,841Feb 21 06:16 PM
Anicetti Vincent RChief Operating OfficerFeb 18Option Exercise7.605,00038,00160,496Feb 20 04:07 PM
Anicetti Vincent RChief Operating OfficerFeb 18Sale21.6410,000216,39052,996Feb 20 04:07 PM
Anicetti Vincent RChief Operating OfficerJan 17Option Exercise7.605,00038,00165,496Jan 22 04:06 PM
Anicetti Vincent RChief Operating OfficerJan 17Sale19.5910,000195,93157,996Jan 22 04:06 PM
Viret Jean-FredericChief Financial OfficerJan 15Option Exercise10.056,31863,49653,159Jan 17 04:11 PM
Viret Jean-FredericChief Financial OfficerJan 15Sale19.856,318125,42446,841Jan 17 04:11 PM
HEALY JAMESDirectorJan 12Option Exercise12.3720,000247,40070,086Jan 13 04:45 PM
HEALY JAMESDirectorJan 09Option Exercise5.0249,994251,00050,086Jan 13 04:45 PM
Anicetti Vincent RChief Operating OfficerDec 16Option Exercise2.502,5006,25121,826Dec 18 04:28 PM
Anicetti Vincent RChief Operating OfficerDec 16Sale18.692,50046,72519,326Dec 18 04:28 PM
Lanfear Dennis MPresident & CEONov 21Sale18.5612,500231,960446,684Nov 25 04:03 PM
Viret Jean-FredericChief Financial OfficerNov 20Option Exercise10.053,15931,7486,462Nov 22 04:09 PM
Lanfear Dennis MPresident & CEONov 20Sale18.00825,00014,850,000459,184Nov 22 06:56 PM
Viret Jean-FredericChief Financial OfficerNov 20Sale19.593,15961,8723,303Nov 22 04:09 PM
Viret Jean-FredericChief Financial OfficerNov 18Sale18.883,11258,7573,303Nov 20 04:22 PM
Anicetti Vincent RChief Operating OfficerNov 14Option Exercise2.502,5006,25121,810Nov 18 04:10 PM
Anicetti Vincent RChief Operating OfficerNov 14Sale19.262,50048,15019,310Nov 18 04:10 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.